Cyclophosphamide
Treatment for Acute Glomerulonephritis
Typical Dosage: 0.5-1 g/m² IV monthly, or daily oral 1-2 mg/kg
Effectiveness
80%
Safety Score
30%
Clinical Trials
1
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
0.5-1 g/m² IV monthly, or daily oral 1-2 mg/kg
Time to Effect
Weeks to 2 months
Treatment Duration
3-6 months induction, then switch to maintenance
Evidence Quality
HIGHConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,000
Monitoring:$3,000
Side Effect Mgmt:$2,000
Total Annual:$6,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$2,400/QALY
QALYs Gained
2.5
Outcome-Based Costs
Cost per Responder
$7,500
Cost per Remission
$10,000
Comparison vs Mycophenolate Mofetil
Cost Difference
+$500/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Cyclophosphamide Outcomes
for Acute Glomerulonephritis
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+80%
Remission Rate
+60%
Common Side Effects
Bone marrow suppression (leukopenia, anemia, thrombocytopenia)
+40%
Infections
+25%
Hemorrhagic cystitis
+15%
Infertility
+25%
Nausea, vomiting, alopecia
+35%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov